What question did this study set out to answer?

This research aims to evaluate the prevalence and trends of artemisinin partial resistance mutations in Plasmodium falciparum in Northwestern Tanzania.

June 6, 2026Frontiers in Genetics0 citationsOpen Access

Temporal trends in artemisinin partial resistance and other antimalarial drug mutations in Plasmodium falciparum from Kagera region, Northwestern Tanzania, 2021–2023

ASAlfred Simkin SMSalehe S. Mandai A(Abebe A. Fola (9543709)

Key Points

This research aims to evaluate the prevalence and trends of artemisinin partial resistance mutations in Plasmodium falciparum in Northwestern Tanzania.
Genotyping of 2,866 P. falciparum isolates from seven districts in Kagera region (2021–2023) using molecular inversion probes.
Assessment of key resistance loci, including the K13 mutation R561H, to characterize mutation prevalence.
Statistical analysis using weighted Spearman correlation for spatial mutation co-localization.
Prevalence of the K13 mutation R561H ranged from 14% to 26%, with a regional increase from 5.5% in 2021 to 6.9% in 2023.
Detection of additional mutations (A675V, V568G, P441L) at low frequencies; DHFR and DHPS mutations near fixation.
Significant spatial co-localization of markers associated with resistance (weighted Spearman R 2 = 0.58, P = 0.045).

Abstract

Artemisinin-based combination therapies (ACTs) remain the cornerstone of malaria treatment, yet the emergence of artemisinin partial resistance (ART-R) in Africa threatens their efficacy. ART-R is primarily associated with mutations in Plasmodium falciparum kelch13 (K13), notably R561H, which has been linked to delayed parasite clearance in East Africa. We genotyped 2,866 P. falciparum isolates from seven districts in Tanzania’s Kagera region (2021–2023) using 121 molecular inversion probes (MIP) targeting key resistance loci to characterize trends in ART-R and other resistance markers. The WHO-validated K13 mutation R561H persisted in border districts of Karagwe and Kyerwa, with prevalence ranging from 14% to 26%, and appeared for the first time in Muleba in 2022 (10.0%) and Bukoba rural district (0.7%) in 2023, indicating eastward spread toward Lake Victoria. Regional prevalence of R561H rose from 5.5% in 2021 to 6.9% in 2023. Additional validated (A675V) and candidate (V568G, P441L) mutations were detected at low frequencies. Markers associated with reduced sensitivity to partner drugs showed minimal change. Early DHFR and DHPS mutations were near fixation and high-level resistance markers (DHFR I164L and DHPS A581G) exhibited marked gradients. These latest mutations are significantly spatially colocalized (weighted spearman R 2 = 0.58, P = 0.045) and co-occur within a number of individual genomes. These results highlight notable variation in mutation prevalence and underscore the importance of high-resolution surveillance to identify emerging hotspots and guide targeted interventions. Sustained molecular monitoring is critical to inform treatment policy, preserve ACT efficacy, and mitigate the risk of widespread resistance across East Africa.

Perguntar à IA

Bookmark

View Full Paper